葵花药业：获得《药物临床试验批准通知书》

Core Viewpoint - Kuaihua Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its pediatric medication, indicating a strategic move to expand its product offerings in the pediatric market [1] Company Summary - Kuaihua Pharmaceutical's wholly-owned subsidiary, Heilongjiang Kuaihua Pharmaceutical Co., Ltd., has been granted a clinical trial approval for its pediatric lung heat cough syrup, aimed at treating acute bronchitis in children [1] - As of the latest report, Kuaihua Pharmaceutical's market capitalization stands at 9.1 billion yuan [1] Industry Summary - In the first half of 2025, the pharmaceutical sector accounted for 99.61% of Kuaihua Pharmaceutical's total revenue, highlighting the company's strong focus on the pharmaceutical industry [1] - Other business segments contributed only 0.39% to the overall revenue, indicating a concentrated business model [1]